Biohaven (BHVN) Competitors $22.14 +0.26 (+1.19%) As of 04/30/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BHVN vs. ROIV, RVMD, LNTH, BBIO, TGTX, LEGN, SRPT, TLX, ADMA, and BPMCShould you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), ADMA Biologics (ADMA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Biohaven vs. Roivant Sciences Revolution Medicines Lantheus BridgeBio Pharma TG Therapeutics Legend Biotech Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares ADMA Biologics Blueprint Medicines Roivant Sciences (NASDAQ:ROIV) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership. Does the media refer more to ROIV or BHVN? In the previous week, Biohaven had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 23 mentions for Biohaven and 14 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.35 beat Biohaven's score of 0.74 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 13 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 9 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ROIV or BHVN? Roivant Sciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Do institutionals and insiders believe in ROIV or BHVN? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 16.0% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend ROIV or BHVN? Roivant Sciences presently has a consensus target price of $17.50, indicating a potential upside of 50.60%. Biohaven has a consensus target price of $62.54, indicating a potential upside of 182.47%. Given Biohaven's stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Biohaven 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Does the MarketBeat Community prefer ROIV or BHVN? Biohaven received 353 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 67.44% of users gave Biohaven an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5578.57% Underperform Votes1521.43% BiohavenOutperform Votes40867.44% Underperform Votes19732.56% Which has better valuation & earnings, ROIV or BHVN? Roivant Sciences has higher revenue and earnings than Biohaven. Roivant Sciences is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$122.59M67.64$4.35B-$0.15-77.47BiohavenN/AN/A-$408.17M-$9.39-2.36 Is ROIV or BHVN more profitable? Biohaven has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Biohaven N/A -225.12%-158.89% SummaryBiohaven beats Roivant Sciences on 10 of the 17 factors compared between the two stocks. Get Biohaven News Delivered to You Automatically Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BHVN vs. The Competition Export to ExcelMetricBiohavenPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.26B$6.90B$5.57B$18.97BDividend YieldN/A3.06%5.11%4.03%P/E Ratio-2.377.4422.4232.71Price / SalesN/A242.72394.1027.84Price / CashN/A65.8538.1817.53Price / Book4.156.516.774.47Net Income-$408.17M$143.21M$3.22B$1.02B7 Day Performance3.46%3.95%3.25%2.26%1 Month Performance-19.75%0.34%0.01%-2.86%1 Year Performance-42.95%2.58%18.00%5.48% Biohaven Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BHVNBiohaven3.6241 of 5 stars$22.14+1.2%$62.54+182.5%-43.0%$2.26BN/A-2.37239Upcoming EarningsAnalyst ForecastGap DownROIVRoivant Sciences2.1666 of 5 stars$11.19+1.6%$17.50+56.4%+6.6%$7.98B$122.59M-74.60860RVMDRevolution Medicines3.7636 of 5 stars$41.47+7.0%$66.67+60.8%+8.3%$7.71B$742,000.00-11.55250Upcoming EarningsAnalyst ForecastPositive NewsLNTHLantheus3.9823 of 5 stars$102.70+0.9%$129.43+26.0%+56.8%$7.03B$1.53B17.09700Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.5498 of 5 stars$35.89-1.2%$53.00+47.7%+49.7%$6.81B$221.90M-12.59400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageTGTXTG Therapeutics3.327 of 5 stars$42.03+1.7%$40.67-3.2%+233.2%$6.67B$329.00M-420.26290Upcoming EarningsPositive NewsGap DownLEGNLegend Biotech2.6303 of 5 stars$34.70+1.2%$78.82+127.1%-20.1%$6.37B$627.24M-36.531,070Positive NewsSRPTSarepta Therapeutics4.678 of 5 stars$61.51+1.8%$158.70+158.0%-50.7%$5.97B$1.90B49.21840TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.57-6.5%$22.00+25.2%N/A$5.94B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownHigh Trading VolumeADMAADMA Biologics1.472 of 5 stars$24.51+12.1%$22.50-8.2%+265.0%$5.82B$426.45M87.54530Upcoming EarningsNews CoveragePositive NewsGap DownHigh Trading VolumeBPMCBlueprint Medicines2.5598 of 5 stars$88.51+1.0%$124.53+40.7%-2.0%$5.66B$508.82M-81.95640Analyst ForecastPositive News Related Companies and Tools Related Companies Roivant Sciences Alternatives Revolution Medicines Alternatives Lantheus Alternatives BridgeBio Pharma Alternatives TG Therapeutics Alternatives Legend Biotech Alternatives Sarepta Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives ADMA Biologics Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BHVN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BHVN Stock Free BHVN Stock Alerts